Table 4.
Multivariate regression analysis of the effect of HLA-C matching score after dUCB transplantation in endpoints in which there was no interaction with conventional HLA-matching at HLA-A,-B, and -DRB1.
| N | HR (95% Confidence interval) | P-value | |
|---|---|---|---|
| RELAPSE£ | |||
| HLA-C match score | |||
| 4/4* | 77 | 1.0 | |
| 3/4 | 108 | 1.0 (0.6–1.6) | 0.92 |
| 2/4 | 211 | 0.7 (0.4–1.1) | 0.15 |
| 1/4 | 62 | 1.0 (0.5–1.7) | 0.87 |
| 0/4 | 57 | 0.9 (0.5–1.7) | 0.80 |
| Worst HLA Match −A, -B, and −DRB1 | |||
| 6/6* | 24 | 1.0 | |
| 5/6 | 102 | 0.5 (0.3–1.1) | 0.09 |
| 4/6 | 256 | 0.6 (0.3–1.2) | 0.16 |
| 3/6 | 106 | 0.6 (0.3–1.3) | 0.22 |
| 2/6 | 27 | 0.5 (0.2–1.5) | 0.24 |
| Disease Risk | |||
| Standard risk* | 311 | 1.0 | |
| High risk | 204 | 1.0 (0.7–1.4) | 0.89 |
| Conditioning | |||
| MAC* | 166 | 1.0 | |
| RIC | 349 | 3.0 (1.9–4.7) | <0.01 |
| Grade II–IV aGVHD | |||
| No* | 305 | 1.0 | |
| Yes | 210 | 0.6 (0.4–0.9) | 0.01 |
| Grade II–IV Acute GVHD£ | |||
| HLA-C match score | |||
| 4/4* | 77 | 1.0 | |
| 3/4 | 108 | 0.9 (0.6–1.5) | 0.68 |
| 2/4 | 211 | 0.9 (0.6–1.4) | 0.70 |
| 1/4 | 62 | 1.0 (0.6–1.8) | 0.94 |
| 0/4 | 57 | 0.8 (0.5–1.5) | 0.54 |
| Worst HLA Match -A, -B, and -DRB1 | |||
| 6/6* | 24 | 1.0 | |
| 5/6 | 102 | 1.1 (0.5–2.2) | 0.81 |
| 4/6 | 256 | 0.8 (0.4–1.7) | 0.65 |
| 3/6 | 106 | 1.4 (0.7–2.9) | 0.38 |
| 2/6 | 27 | 1.1 (0.5–2.6) | 0.80 |
| Conditioning | |||
| MAC* | 166 | 1.0 | |
| RIC | 349 | 0.6 (0.5–0.8) | <0.01 |
| Chronic GVHD£ | |||
| HLA-C match score | |||
| 4/4* | 77 | 1.0 | |
| 3/4 | 108 | 1.0 (0.5–1.9) | 0.89 |
| 2/4 | 211 | 1.3 (0.7–2.5) | 0.44 |
| 1/4 | 62 | 1.0 (0.4–2.4) | 0.95 |
| 0/4 | 57 | 1.5 (0.7–3.5) | 0.31 |
| Worst HLA Match -A, -B, and -DRB1 | |||
| 6/6* | 24 | 1.0 | |
| 5/6 | 102 | 0.5 (0.2–1.1) | 0.09 |
| 4/6 | 256 | 0.5 (0.2–1.1) | 0.09 |
| 3/6 | 106 | 0.6 (0.2–1.5) | 0.30 |
| 2/6 | 27 | 0.5 (0.2–1.7) | 0.29 |
| Conditioning | |||
| MAC* | 166 | 1.0 | |
| RIC | 349 | 0.9 (0.6–1.4) | 0.68 |
| Neutrophil Engraftment by Day +42£ | |||
| HLA-C match score | |||
| 4/4* | 77 | 1.0 | |
| 3/4 | 108 | 0.8 (0.5–1.1) | 0.13 |
| 2/4 | 211 | 0.8 (0.6–1.1) | 0.15 |
| 1/4 | 62 | 1.0 (0.7–1.5) | 0.90 |
| 0/4 | 57 | 0.9 (0.6–1.3) | 0.52 |
| Worst HLA Match -A, -B, and -DRB1 | |||
| 6/6* | 24 | 1.0 | |
| 5/6 | 102 | 1.0 (0.6–1.6) | 0.93 |
| 4/6 | 256 | 0.9 (0.5–1.4) | 0.53 |
| 3/6 | 106 | 0.7 (0.4–1.2) | 0.21 |
| 2/6 | 27 | 0.7 (0.4–1.3) | 0.23 |
| Conditioning | |||
| MAC* | 166 | 1.0 | |
| RIC | 349 | 1.9 (1.5–2.4) | <0.01 |
| Age | |||
| <18* | 47 | 1.0 | |
| 18–34 | 97 | 0.7 (0.5–1.0) | 0.08 |
| 35+ | 371 | 0.9 (0.6–1.2) | 0.42 |
| CMV serostatus | |||
| Negative* | 212 | 1.0 | |
| Positive | 303 | 0.8 (0.7–1.0) | 0.06 |
| Platelet Engraft£ | |||
| HLA-C match score | |||
| 4/4* | 77 | 1.0 | |
| 3/4 | 108 | 1.0 (0.6–1.4) | 0.81 |
| 2/4 | 211 | 0.8 (0.6–1.2) | 0.36 |
| 1/4 | 62 | 0.8 (0.5–1.3) | 0.43 |
| 0/4 | 57 | 0.7 (0.5–1.2) | 0.19 |
| Worst HLA Match -A, -B, and -DRB1 | |||
| 6/6* | 24 | 1.0 | |
| 5/6 | 102 | 0.9 (0.5–1.7) | 0.92 |
| 4/6 | 256 | 0.8 (0.4–1.4) | 0.78 |
| 3/6 | 106 | 0.8 (0.4–1.5) | 0.53 |
| 2/6 | 27 | 0.7 (0.3–1.5) | 0.32 |
| Conditioning | |||
| MAC* | 166 | 1.0 | |
| RIC | 349 | 1.7 (1.3–2.1) | <0.01 |
| CMV serostatus | |||
| Negative* | 212 | 1.0 | |
| Positive | 303 | 0.8 (0.7–1.0) | 0.05 |
Abbreviations: HLA, human leukocyte antigen; dUCB, double umbilical cord blood; N, number of patients; CI, confidence interval; GVHD, graft-vs-host disease.
*
Reference group
£
Stratified by transplant center